-

Agilent to Showcase Their Commitment to Sustainability at analytica virtual 2020

LC instruments receive ACT labels from My Green Lab

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that their 1220, 1260, and 1290 Infinity II LC product families have received the My Green Lab accountability, consistency, and transparency (ACT) certification. Recognition of these products by My Green Lab highlights Agilent's commitment to pursuing sustainability throughout the production and lifecycle of its analytical equipment. Agilent will showcase these accredited products at the 2020 analytica virtual industry trade fair.

No longer a side topic in science and industry, sustainability has become a key strategic element, especially as part of decisions around the purchase of instruments for "labs of the future." With a growing need – and pressure – to factor in environmental responsibility, more and more labs are seeking ways to reduce their environmental impact through the purchase of more sustainable equipment. Additionally, the success of labs seeking to attract the best personnel is seen as strongly linked to their ability to offer an eco-conscious working environment.

A leader in life sciences, diagnostics, and applied chemical markets, Agilent is amongst the first global analytical instrumentation manufacturing companies to be externally audited for the environmental impact of their gas and liquid chromatographs. These newly certified Agilent products give customers a clearer path for reducing the environmental impact of their labs, while simultaneously improving laboratory working conditions and demonstrating their own commitment to sustainability.

“Innovation is at the forefront of Agilent’s core company values,” said Darlene Solomon, senior vice president, and chief technology officer for Agilent Technologies. “We remain focused on innovation through differentiated laboratory solutions and transformation of the customer experience, and sustainability is a priority. Continuous improvement of our products and services, in terms of the benefits they deliver as well as the environmental impact associated with their production and operation is a key driver of our efforts.”

As a nonprofit organization run "for scientists, by scientists," My Green Lab is dedicated to "fundamentally and permanently improving the sustainability of scientific research." They strive to unify scientists, vendors, designers, energy providers, and others toward research that reflects the highest standards of social and environmental responsibility.

Agilent’s Infinity II liquid chromatography (HPLC) instruments underwent the independent audit process and received their labels in June while the gas chromatography instruments are currently undergoing the certification process. Visit our booth at analytica virtual to see the instruments with their labels, and to find out more.

For more information about the ACT label, visit https://act.mygreenlab.org/ .

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Catherine Kaye
Agilent Technologies
+447775 410632
catherine.kaye@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Catherine Kaye
Agilent Technologies
+447775 410632
catherine.kaye@agilent.com

More News From Agilent Technologies Inc.

Agilent Showcases Cancer Research Solutions at AACR 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand f...

Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica...
Back to Newsroom